Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with concurrent chemoradiotherapy for locally advanced cervical cancer
ChiCTR2300068704Phase 2Not yet recruiting
- Sponsor
- Jiamusi Cancer Hospital
- Start
- Jan 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in Cervical Cancer (CC), sponsored by Jiamusi Cancer Hospital. Primary endpoint: Objective remission rate (ORR). Planned start Jan 2023; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2300068704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068704.